14/02/2024
PHARMENA SA EXPANDS DISTRIBUTION TO AUSTRALIA AND NEW ZEALAND MARKETS
PHARMENA S.A. has signed an annex to the distribution agreement expanding the scope of exclusive distribution of dietary supplements containing the 1-MNA molecule under the Endotelio brand to the markets of Australia and New Zealand.
14/01/2024
PHARMENA SA BEGINS COLLABORATION WITH AMAZON EU
Pharmena S.A. has initiated a collaboration with Amazon for the sale of the Company's dietary supplements portfolio on Amazon's e-commerce platforms in Europe.
14/09/2023
EUROPEAN PATENT GRANTED
The European Patent Office has granted a patent covering the applications of 1-MNA for preventing and reducing the risk of cardiovascular events associated with elevated CRP levels. This patent ensures patent protection for Pharmena SA in the aforementioned territories, including France, Germany, Austria, Finland, Italy, Denmark, the Netherlands, Belgium, Sweden, Poland, Ireland, Switzerland/Liechtenstein, Spain, Turkey, and the United Kingdom.
14/09/2023
PHARMENA PLANS TO EXPAND ITS OPERATIONS
Pharmena intends to develop and introduce an innovative medical device for use in difficult-to-heal wounds, including diabetic foot ulcers, to the market. The medical device is planned for use in home settings. The introduction of the product is subject to clinical trials and medical device certification. The planned period for trials and certification is approximately 3 years. The Company intends to finance the project with its own funds or obtain additional financing through grants from EU funds. The global market for difficult-to-heal wounds exceeded USD 20 billion in 2022, with nearly 20% of the market attributed to products for home use. The market is estimated to grow at a rate of approximately 5.5% annually over the next 10 years.
30/06/2023
Pharmena sold its dermocosmetic business
Pharmena SA sold its dermocosmetic business to Laboratorio Genove, an international company based in Barcelona that is specialized in dermo-cosmetic products. As part of the transaction, Pharmena sold all shares of Dermena Lab and an organized part of the enterprise related to dermocosmetic business. After the sale of the dermocosmetic business, Pharmena has a plan to continue its activities in the field of sales of dietary supplements, present a potential candidate for an innovative 1-MNA-based products and start work on other projects based on this active substance.
15/12/2022
PHARMENA SA SIGNS DISTRIBUTION AGREEMENTS FOR USA, CANADA, AND MEXICO MARKETS
The Company has signed a distribution agreement with Longevity Lunch Lab. LLC for the sale of dietary supplements containing the 1-MNA molecule under the Endotelio brand in the markets of the United States, Canada, and Mexico.
30/03/2022
PATENT GRANTED IN MEXICO
The Mexican Patent Office has granted a patent covering the applications of 1-MNA for preventing and reducing the risk of cardiovascular events associated with elevated CRP levels. This patent provides protection for the Company in the aforementioned territory of Mexico.
28/06/2021
PRECLINICAL STUDIES COMPLETED TO DETERMINE EFFECTIVE DOSE OF 1-MNA
Preclinical studies on animal models commissioned by the Company were completed on June 25, 2021, by Labcorp Early Development Laboratories Ltd. The studies revealed the anti-inflammatory and anti-fibrotic effects of 1-MNA. In a animal model of lung fibrosis, 1-MNA at a dose of 50mg/kg reduced lung fibrosis by 28% compared to placebo, demonstrating greater efficacy than two reference drugs used in the study, currently on the market: nintedanib (17% reduction) and fluticasone (14% reduction).
29/03/2021
PATENT GRANTED IN THE RUSSIAN FEDERATION
The Russian Patent Office has granted a patent covering the applications of 1-MNA for preventing and reducing the risk of cardiovascular events associated with elevated CRP levels. This patent provides protection for the Company in the aforementioned territory of the Russian Federation.
16/02/2021
PRECLINICAL STUDY INITIATED TO DETERMINE EFFECTIVE DOSE OF 1-MNA IN SARS-COV-2 INFECTION
On January 21, 2021, the second of three planned preclinical studies on animal models commissioned by the Company began at Covance Inc. The study involves evaluating 1-MNA in a model of lung inflammation. The planned studies on animal models aim to determine the effective dose of the drug candidate in Sars-Cov-2 infection, which is essential for conducting clinical trials in humans.
21/01/2021
COMMENCEMENT OF PRECLINICAL STUDY TO DETERMINE EFFECTIVE DOSE OF 1-MNA, A DRUG CANDIDATE IN SARS-COV-2 INFECTION
On January 21, 2021, the second of three planned preclinical studies on animal models commissioned by Covance Inc. on behalf of the Company commenced. The study involves evaluating 1-MNA in a model of lung inflammation. The planned studies on animal models aim to determine the effective dose of the drug candidate in Sars-Cov-2 infection. Establishing the effective dose of the drug candidate 1-MNA is essential for conducting clinical trials in humans in Sars-Cov-2 infection.
30/11/2020
SIGNING OF SUBSCRIPTION AGREEMENT FOR SERIES F SHARES
On November 30, 2020, a subscription agreement for Series F shares was signed. Consequently, the issuance of Series F shares was completed. Pelion S.A. acquired 153,000 (one hundred fifty-three thousand) new ordinary Series F bearer shares with a nominal value of 0.10 PLN (ten grosz) each.
17/11/2020
PHARMENA INITIATES PRECLINICAL STUDIES TO DETERMINE THE MAXIMUM TOLERATED DOSE OF 1-MNA, A DRUG CANDIDATE FOR SARS-COV-2 INFECTION
On November 17, 2020, the Company commenced the first of three planned preclinical studies on animal models conducted by Covance Inc. The planned studies on animal models aim to determine the effective dose of the drug candidate in SARS-Cov-2 infection. Establishing the effective dose of the 1-MNA drug candidate is necessary for conducting clinical trials in humans with SARS-Cov-2 infection.
24/08/2020
DEVELOPMENT OF RESEARCH PLANS FOR 1-MNA IN SARS-COV-2 INFECTION
The company has developed 08a research plan for 1-MNA in viral infections, including SARS-Cov-2 infection. The plan includes the development of the project in the scope of preclinical studies and clinical trials in humans (phase I and II). The plan was developed in collaboration with a leading American entity specializing in the organization of clinical research processes, known as a Contract Research Organization (CRO).
20/12/2019
DETERMINATION OF EFFECTIVE DOSE OF 1-MNA IN PRECLINICAL STUDY FOR PAH INDICATION
On December 19, 2019, the Company received the results of a preclinical study in an animal model for Pulmonary Arterial Hypertension (PAH), conducted through its subsidiary, Cortria Corporation, based in the USA. In the aforementioned model, the impact of 1-MNA on PAH was evaluated at doses ranging from 60 mg/kg to 480 mg/kg. Improvement in hemodynamic parameters and body weight gain was observed in animals treated with a dose of 60 mg/kg of 1-MNA.
20/12/2019
PHARMENA SA COMMENCES COLLABORATION WITH AMAZON EU FOR THE SALE OF DERMOCOSMETICS
Pharmena S.A. has initiated a global collaboration with Amazon EU for the sale of dermocosmetics from the Company's portfolio on Amazon's e-commerce platforms. At the beginning of the collaboration, the offering includes 19 products from the Company and will target the European market.
16/10/2019
PHARMENA INTRODUCES DERMOCOSMETICS FOR SALE IN CHINA
The first products of the Company have been introduced for sale in China, Hong Kong, Macau, and Taiwan by a Chinese distributor on the T-mall online platform - the largest e-commerce platform in Asia for retail customers (B2C) and the fifth most visited website in the world. The T-mall platform is the second platform after Taobao where Pharmena products can be purchased in the Chinese market.
10/07/2019
POSITIVE RESULTS FOR 1-MNA IN A PRECLINICAL STUDY IN THE INDICATION OF NASH
On July 10, 2019, Pharmena received the results of a preclinical study in the STAMTM animal model for Non-Alcoholic Steatohepatitis (NASH), conducted through its subsidiary, Cortria Corporation, based in the USA. In the aforementioned model, a positive, significant impact was observed on key parameters of non-alcoholic fatty liver disease development. The effective dose range of the drug 1-MNA in the studied model was determined to be between 200 mg/kg and 800 mg/kg.
02/04/2019
PHARMENA ENTERED INTO A CONTRACT FOR CONDUCTING PRECLINICAL STUDIES IN PAH AS PART OF THE 1-MNA DRUG PROJECT
On April 2, 2019, Cortria Corporation, a subsidiary of PHARMENA S.A., entered into a master agreement with the research center - CorDynamics, Inc. based in Chicago, USA, regarding cooperation in preclinical studies on animal models. Under the aforementioned master agreement, Pharmena, through its subsidiary Cortria Corporation in the USA, plans to initiate preclinical studies of the drug 1-MNA in an animal model for Pulmonary Arterial Hypertension (PAH) to determine the effective dose of the drug 1-MNA for future phase IIB clinical trials. For this purpose, based on the master agreement concluded, the Company intends to commission the conduct of the study on an animal model.
22/02/2019
PHARMENA ENTERED INTO A CONTRACT FOR CONDUCTING PRECLINICAL STUDIES IN NASH AS PART OF THE 1-MNA DRUG PROJECT
On February 22, 2019, Cortria Corporation, a subsidiary of PHARMENA S.A., received a signed master agreement with the research center - SMC Laboratories, Inc. based in Tokyo, Japan, regarding cooperation in preclinical studies on animal models. Pharmena, through its subsidiary Cortria Corporation in the USA, plans to initiate preclinical studies of the drug 1-MNA in an animal model for Non-alcoholic Steatohepatitis (NASH) to determine the effective dose of the drug 1-MNA for future phase IIB clinical trials.
11/12/2018
PHARMENA INTRODUCED MENAVITIN CARDIO DIETARY SUPPLEMENT TO THE POLISH MARKET
MENAVITIN CARDIO is the first dietary supplement under the umbrella brand MENAVITIN. The product is recommended for adults looking to support the proper functioning of the heart. Its distribution will take place through pharmaceutical wholesalers, pharmacy chains, and online pharmacies within the pharmacy channel.
13/08/2018
1-MNA AS A NEW FOOD INGREDIENT
The European Commission Regulation allowing the introduction of 1-MNA as a new food was published in the Official Journal of the European Union on August 13 of this year. The regulation authorizes 1-MNA as a new food ingredient and additionally grants the Company a five-year data exclusivity protection contained in the application for 1-MNA authorization, thus providing exclusive rights to introduce food containing 1-MNA for a period of 5 years from the date of authorization for the new food.
02/01/2018
DISTRIBUTION OF PHARMENA SA PRODUCTS IN EGYPT, QATAR, AND BAHRAIN
Pharmena has commenced collaboration with an Egyptian partner for the exclusive distribution of dermocosmetics in Egypt, Qatar, and Bahrain.
01/10/2016
Eagles of the “Wprost” weekly
Eagles of the “Wprost” weekly Category: "The most dynamically developing companies in the Łódź Voivodeship"
29/06/2016
PHARMENA S.A. QUALIFIED FOR THE NEWCONNECT LEAD SEGMENT
The Management Board of the Warsaw Stock Exchange S.A. has decided that PHARMENA S.A. has once again been qualified for the NewConnect Lead segment. The nomination to this prestigious segment of companies was a result of the high liquidity of PHARMENA S.A. shares and the reliable fulfillment of information obligations and corporate governance principles.
23/03/2016
Diamond of the Forbes Magazine
Pharmena SA was awarded among companies with revenue ranging from PLN 5 million to 50 million.
14/03/2016
PHARMENA SA EXPANDS COOPERATION TO NEW MARKETS
As part of the current distribution agreement, the company has expanded its cooperation with a distributor to the Chinese and Taiwanese markets. Collaboration with the aforementioned distributor aims to expand into new markets beyond the country's borders, which is one of the elements of the Company's Strategy regarding the expansion of distribution channels for dermocosmetics.
14/03/2016
QUALIFICATION OF PHARMENA S.A. SHARES FOR THE NCINDEX30 INDEX
Based on the resolution of the GPW Management Board of July 3, 2007, a quarterly review of the NCIndex30 portfolio was conducted by the Warsaw Stock Exchange. The NCIndex30 index includes a portfolio of the 30 most liquid companies listed on NewConnect. According to the index methodology, Pharmena S.A. shares re-entered the NCIndex30 after the session on March 18, 2016. This is another distinction for Pharmena S.A., alongside the qualification of Pharmena S.A. shares for the prestigious NC LEAD segment.
21/01/2016
PHARMENA SA SIGNING AGREEMENT FOR PRODUCT DISTRIBUTION IN INDIA
On January 21, 2016, the company received a signed agreement regarding the distribution of its products in the Indian market. Initiating collaboration with the aforementioned distributor aims to expand into new markets beyond the country's borders, which is one of the elements of implementing the Company's strategy to broaden the distribution channels of dermocosmetics.
13/12/2015
QUALIFICATION OF PHARMENA S.A. FOR THE NEWCONNECT LEAD SEGMENT
In accordance with the announcement from the Management Board of the Warsaw Stock Exchange on December 28, 2015, PHARMENA S.A. has once again been qualified for the NewConnect Lead segment. The nomination to this prestigious segment of companies was a result of the high liquidity of PHARMENA S.A. shares and the reliable fulfillment of informational obligations and corporate governance principles.
20/10/2015
Łódź Voivodeship Special Award for 2015
Granted by voivodeship governor and voivodeship marshal for investing in researches, development scientific description and implementation of innovative products.
15/10/2015
SIGNING OF THE DISTRIBUTION AGREEMENT FOR PRODUCTS IN THE UNITED ARAB EMIRATES AND OMAN MARKET
On October 15, 2015, the Company received a signed agreement regarding the distribution of its products in the markets of the United Arab Emirates and Oman. According to the Board's assessment, the above agreement may have a significant impact on increasing the sales of dermocosmetics in the coming years. Commencing cooperation with the mentioned distributor aims to expand into new markets beyond the country's borders, which is one of the elements of implementing the Company's strategy to broaden the distribution channels of dermocosmetics.
18/09/2015
SIGNING OF THE DISTRIBUTION AGREEMENT FOR PRODUCTS IN KUWAIT
On September 18, 2015, the Company received a signed agreement regarding the distribution of its products in the Kuwaiti market. According to the Board's assessment, the above agreement may have a significant impact on increasing the sales of dermocosmetics in the coming years. Commencing cooperation with the mentioned distributor aims to expand into new markets beyond the country's borders, which is one of the elements of implementing the Company's strategy to broaden the distribution channels of dermocosmetics.
15/09/2015
SIGNING OF THE DISTRIBUTION AGREEMENT FOR PRODUCTS IN SOUTH KOREA
The Management Board of Pharmena S.A. informs that on September 15, 2015, the Company entered into an agreement regarding the distribution of its products in the South Korean market. According to the Board's assessment, the above agreement may have a significant impact on increasing the sales of dermocosmetics in the coming years.
19/08/2015
EXPANSION OF COOPERATION WITH ROSSMANN DRUGSTORE CHAIN
In August of this year, the company expanded its cooperation with the Rossmann drugstore chain, increasing the availability of selected products from the Dermena line from 214 to 1050 stores of this chain in Poland. Rossmann is one of the largest drugstore chains in Europe and a leader in its industry in Poland. The share of Rossmann drugstores in the sale of products in the chemical-cosmetic category is 26%. Rossmann drugstores are present in 400 Polish cities, both in shopping centers of major cities and in smaller towns. Every day, 650,000 people shop at Rossmann drugstores.
24/07/2015
Pharmena SA is the market innovation leader of 2015
Within the scope of the national promotional programme organised by the editorial office of Strefa Gospodarki, PHARMENA SA was awarded the title of Market Innovation Leader 2015 - Quality, Creativity, Effectiveness". The title granted to the Company is an objective confirmation of the innovativeness and competitiveness of products offered by the Company. It also stands as a reliable guarantee ensuring market reliability, consistence and stability of the company.
22/06/2015
DECISION ON GRANTING A PATENT IN THE USA
The United States Patent and Trademark Office has made a decision to grant a patent for the application of 1-methylnicotinamide (1-MNA) in correcting lipid profile disorders (reducing TG, increasing HDL, and reducing total cholesterol) through dietary supplement administration. This patent provides the company with patent protection in the aforementioned scope within the United States of America. This is another patent (previous ones were obtained in, among others, the USA, Europe, the Russian Federation, Mexico, Canada, Australia, and China) that the company has obtained as part of patent applications concerning the application of selected pyridine salts in vascular protection. The company has made a series of patent applications in previous years to ensure protection worldwide.
26/02/2015
Pharmena among “Forbes Diamonds 2015”
Pharmena SA has been placed, for the first time, in the prestigious circle of FORBES DIAMONDS 2015. The ranking of the monthly magazine Forbes assesses commercial and production companies that have been increasing their values at the fastest rate. In the Lodz region, there were 84 companies honoured with the title "Forbes Diamond” in three categories, according to the amount of their income. Pharmena SA took the 4th place in the Lodz region and 88th place in Poland in the category of companies whose income ranges from 5 to 50 million PLN.
02/02/2015
SIGNING OF AGREEMENT WITH DOZ S.A.
On January 30, 2015, the Company signed an agreement with DOZ S.A. in Warsaw - the operator of the "Dbam o zdrowie" pharmacy network. The subject of the agreement is the provision by DOZ S.A. of marketing services to Pharmena S.A. aimed at increasing the sales of Pharmena S.A. products in "Dbam o zdrowie" pharmacies. "Dbam o zdrowie" pharmacies are the largest network of pharmacies in Poland operating under a common brand, comprising approximately 1100 outlets. DOZ S.A. is part of the international holding company CEPD NV, which is a member of the Pelion S.A. capital group.
12/12/2014
OBTAINING PATENT IN CANADA
On December 11, 2014, CORTRIA CORPORATION, a subsidiary of PHARMENA S.A., received notification that the Canadian Patent Office has granted a patent, providing protection for the use of 1-methylnicotinamide (1-MNA) in combination with statins for treating lipid profile disorders (lowering triglyceride levels and increasing "good" HDL cholesterol levels) in Canada. This is another patent (previous ones were obtained in, among others, the USA, Europe, and Japan) obtained by CORTRIA as part of patent applications related to the use of selected pyridinium salts.
11/12/2014
PLANNED NEW PRODUCTS IN DERMATOLOGY
Between 2015 and 2018, the Company plans to introduce over 50 new dermocosmetic products, reaching new target groups. In the first half of 2015, the Company plans to launch 15 new products. Simultaneously, development work is underway on another 17 products, which should be introduced to the market around the turn of 2015/2016.
10/11/2014
DECISION ON PATENT GRANT IN THE USA
On November 8, 2014, Pharmena received notification that the United States Patent and Trademark Office had decided to grant a patent for the use of 1-methylnicotinamide (1-MNA) in the treatment of atherosclerosis, associated with the elevation of prostacyclin levels. This patent provides the Company with patent protection in the aforementioned area within the United States of America. This is another patent (previous ones were obtained in, among others, the USA, Europe, the Russian Federation, Mexico, Canada, Australia, and China) that the Company has obtained as part of patent applications related to the use of selected pyridine salts in vascular protection. The Company has made a series of patent applications ensuring protection worldwide in previous years.
31/10/2014
TOXICITY STUDIES OF 1-MNA FOR THE DIETARY SUPPLEMENT PROJECT CONCLUDED SUCCESSFULLY
On October 30, 2014, Pharmena received the full report from the subchronic (90-day) toxicity studies conducted on animal models. These studies were commissioned in March 2014 to supplement the application for the authorization of 1-MNA as a new food ingredient (dietary supplement) under Article 4 of Regulation No. 258/97. The analysis of the toxicity study results showed very good tolerance and high safety of the tested substance, 1-MNA. The studies did not reveal any adverse effects attributable to the tested substance.
31/10/2014
COMMENCEMENT OF COOPERATION WITH LUBFARM S.A.
On October 28, 2014, the Company initiated direct cooperation with the pharmaceutical wholesaler Lubfarm S.A. Lubfarm has over 20 years of experience in distributing pharmaceutical products in the southeastern region of Poland. Its reach covers the provinces of Lublin, Podkarpackie, Świętokrzyskie, Małopolskie, the eastern part of Mazowieckie, and Śląskie, as well as the southern part of Podlaskie. The Management Board of Pharmena S.A. estimates that the collaboration with Lubfarm will improve the availability of Pharmena products in the eastern and southern parts of Poland.
12/03/2014
SIGNING OF AGREEMENT FOR TOXICITY STUDIES WITHIN THE 1-MNA DIETARY SUPPLEMENT PROJECT
On March 12, 2014, Cortria Corporation, a subsidiary of PHARMENA S.A., entered into an agreement to conduct subchronic toxicity studies (90-day) on animal models, aiming to supplement the application for the authorization of 1-MNA as a new food ingredient under Article 4 of Regulation No. 258/97. The company plans to commence the subchronic toxicity studies on April 1st of this year and, upon their completion, present the results to the Advisory Committee on Novel Foods and Processes (ACNFP), which, in collaboration with the Food Standards Agency (FSA), evaluates the application for the authorization of 1-MNA as a new food ingredient.
06/03/2014
COMMENCEMENT OF COLLABORATION WITH EURO-APTEKA PHARMACY CHAIN
The company has commenced collaboration with the Euro-Apteka pharmacy chain in Poland for the sale of products from the Dermena line as well as marketing activities. Euro-Apteka is a pharmacy chain operating in Poland since 2001. The chain is part of the international Euro Apotheca Holding. In Poland, Euro-Apteka is present in 35 cities and currently operates 65 pharmacies.
21/02/2014
OBTAINING PATENT IN JAPAN
On February 21, 2014, Cortria Corporation, a subsidiary of PHARMENA S.A., received notification that the Japanese Patent Office has granted a patent, providing patent protection for the use of 1-methylnicotinamide (1-MNA) in combination with statins for treating lipid profile disorders (lowering triglyceride levels and raising "good" HDL cholesterol levels) in Japan.
14/02/2014
INITIATING COOPERATION WITH MEDIQ APTEKA PHARMACY NETWORK
On February 14, 2014, the company commenced collaboration with the Mediq Apteka pharmacy network in Poland, encompassing the sale of products from the Dermena line and marketing activities. The Mediq Apteka network comprises 190 company-owned pharmacies and 79 franchised ones.
14/02/2014
INITIATING COOPERATION WITH THE DR. MAX PHARMACY NETWORK
On February 14, 2014, the company commenced collaboration with the Dr. Max Polska pharmacy network in Poland, encompassing the sale of products from the Dermena line and marketing activities. Dr. Max Polska is one of the four largest pharmacy chains in the country. The company has a strong position in the pharmaceutical market and is part of the international Dr. Max holding, which also operates in the Czech Republic and Slovakia. In Poland, the pharmacies serve over 450,000 customers monthly, shopping in 101 locations nationwide. The company also specializes in cooperation with clinics and medical offices, supporting the daily work of doctors and medical staff.
03/04/2013
OBTAINING A PATENT IN THE USA
On April 3, 2013, CORTRIA CORPORATION, a subsidiary of PHARMENA S.A., received notification that the United States Patent and Trademark Office had decided to grant a patent, providing additional patent protection for the use of 1-methylnicotinamide (1-MNA) in combination with statins in the treatment of lipid profile disorders (lowering triglyceride levels and increasing "good" HDL cholesterol levels) in the United States of America. This patent is an extension of the patent obtained by CORTRIA CORPORATION in March 2012.
22/03/2013
OBTAINING A PATENT IN EUROPE
On March 22, 2013, CORTRIA CORPORATION, a subsidiary of PHARMENA S.A., received notification that the European Patent Office had decided to grant patent No. EP 2026651. The above patent will provide the Company with patent protection for the oral use of 1-methylnicotinamide (1-MNA) in combination with non-steroidal anti-inflammatory drugs in the treatment of pain and inflammatory conditions of various origins in the leading European markets, including the following countries: Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Greece, Spain, Netherlands, Ireland, Iceland, Liechtenstein, Lithuania, Luxembourg, Monaco, Germany, Poland, Portugal, Romania, Slovakia, Slovenia, Switzerland, Sweden, Turkey, Hungary, United Kingdom, Italy.
30/11/2012
Company’s anniversary celebrations
The post-industrial interiors of andel's hotel restaurant in Łódź hosted a ceremonial gala celebrating 10th anniversary of the Pharmena company. The company founders and those who had a significant contribution to its success received commemorative statuettes from the President of the Board. All present guests had a chance to recollect the company’s beginnings and hear about its future plans. The event’s cordial atmosphere was intensified by Stanisław Soyka’s performance.
27/11/2012
Pharmena SA on a conference held by the Association of Individual Investors
At the invitation of the Association of Individual Investors in Poland, Pharmena SA was a guest on a “Professional Investor” conference, which took place in Jachranka (near Warsaw) on 23rd-25th November 2012. During the “Workshops of Practical Knowledge”, which concentrated on practical expertise on stock exchange investments, the Company’s President of the Board – Konrad Palka talked about the idea of commercialisation of biotechnological projects. The conference “Professional Investor” is the second largest meeting of individual investors in Poland.
17/06/2011
Company’s HQ address change
The Company Pharmena SA has moved its headquarters. Currently, the Company’s office is situated in the very centre of Łódź.
06/10/2010
Pharmena SA in NC LEAD segment
On 30th September 2010, the Management Board of Warsaw Stock Exchange S.A. announced a list of companies, which were qualified to NewConnect Lead segment, and Pharmena SA was one of them. This is yet another nomination of the Issuer for the NewConnect market segment of leading companies.
25/08/2008
PHARMENA’S debut at New Connect
On August 25, 2008, PHARMENA S.A. joined the Exchange Members listed at the Warsaw Stock Exchange. In the alternative turnover system of New Connect, 5.73 million of series A shares and 524,260 series B shares are listed. The Company is going to allocate the gained funds to further support research in the United States and Canada, as well as marketing of the actual products.
04/06/2008
Pharmena in New Connect – New issue of the Company shares
The Company has issued new Series B shares to the value of PLN 13.6 million – as part of its private placement. Almost 100% of the issue has been taken by financial institutions. Next Pharmena intends to enter on the Stock Exchange in the New Connect market. The successful issue of the shares was aimed at raising extra funds for financing further research in the United States and Canada and marketing the current products.
13/04/2008
Transformation of Pharmena Co. Ltd. into Pharmena Joint-Stock Co.
Due to the planned private placement and entering the Company in the Alternative Trading System New Connect market organized by the Warsaw Stock Exchange S.A. on April 17, 2008, Pharmena has transformed itself as a legal entity – from a limited liability company into a joint-stock company.
28/11/2007
PHARMENA – Winner of the Lodz Region Governor’s Business Award
Regional business leaders awarded The Lodz Region Governor, Witold Gwiazda, has given business awards to the region’s best companies. Nine managers received statuettes designed by a Lodz-based sculptor Kazimierz Karpiński, and three others were given occasional diplomas. The Lodz Region Governor’s Business Award is the only regional state award, of honourable nature, and this year’s was its fourth consecutive edition. In their brand and advertising materials, the laureates may use the title „Winner of the Lodz Region Governor’s Business Award 2007”. The companies awarded with diplomas may use the title: „Honoured in the Lodz Region Governor’s Business.
12/10/2007
Launch Of Clinical Studies For New Dyslipidemia Agent In North America
Clinical studies of a new drug candidate for the treatment of dyslipidemia are initiated in North America by Pharmena's partner.
03/09/2007
First Polish Drug in the USA
In the second half of 2007, in the USA and Canada there will be launched another stage of clinical studies of an innovative drug for dislipidemia – lipid profile disorder (cholesterol and triglycerides). Pilot basic research has been carried out in Poland. The drug patent holder is PHARMENA, which company has transferred the know-how to Pharmena North America Inc., established in August of 2005. The licence agreement, based on the patent held by the Lodz-based company, provides for relevant studies to be carried out in the USA and Canada, and possibly for the drug to be commercialised. If these studies are successful, there is a chance that this will be the first drug, developed by the Polish scientific thought, to be registered in the USA. SHORTCUTS Company Research Products News Investor relations Contact WHAT WE DO? New product development Drug research Dietary supplement PRODUCTS Endotelio CONTACT PHARMENA S.A. ul. Gdańska 47/49 90-729 Łódź +48 728 510 293 biuro@pharmena.eu
06/12/2006
Pharmena North America Inc. Has Attracted A New Investor
In November of 2006, Domain Associates, L.L.C, a leading Venture capital firm, invested in Pharmena North America Inc. Domain Associates focuses on investing in promising enterprises in the biotechnology and pharmaceutical sectors. Since its formation in 1985, the fund has participated in the growth and success of more than 180 companies.
03/08/2005
Pharmena North America Inc. Formation
In August, PHARMENA formed Pharmena North America Inc. (PNAI), headquartered in Boston, to conduct clinical development in the USA and Canada. PNAI’s objective is to develop and market in North America product candidate produced from research and development activities at PHARMENA.
20/05/2005
PHARMENA - Modern Technology Leader
The New Technologies Institute of Lodz, supporting entrepreneurship and Lodz’s promotion as a city of new technologies, has organised the „Modern Technology Leader” Competition. The event’s objective is to distinguish and award companies that apply modern technologies and innovative solutions. The competition has three categories: small, medium, and large businesses. The chapter awarded our Company, granting PHARMENA the " Modern Technology Leader" title in the small entrepreneurs category.
25/11/2004
MNA+ Therapeutic Function Discovery Awarded at the 53rd „Brussels Eureka-2004
The "MNA+ therapeutic function discovery" was presented at the 53rd „Brussels Eureka-2004" World Exhibition of Innovation, Research, and New Technologies „Brussels Eureka-2004". The exhibition was held between 16 - 21 November in Brussels. The invention authors were awarded with the silver medal. Also, they received a special mention for creative courage.
10/09/2003
1-Methylnicotinamide Chloride Research Findings Unveiled at the 4th Technology Congress
Research findings regarding 1-Methylnicotinamide chloride were unveiled in a plenary lecture on 10 September, 2003 at the 4th Chemical Technology Congress in Lodz. The lecturer was Professor Jerzy Gębicki. The congress in Lodz was attended by more than 500 scientists.